+A -A

Tabela:
Comparative View:

3Q17 Create chart
Net sales revenues 1,019,521
Change in Fair Value of Biological Assets 40,027
Cost of Goods Sold -628,298
Depreciation / Amortization / exhaustion -104,069
Exhaustion of biological assets -30,372
Gross Profit 296,809
Selling Expenses -165,861
General and Administrative Expenses -36,257
Management Compensation -3,881
Other Operating Compensation 59,809
Equity income from subsidiaries 0
Operating Profit before Financial Income and Equity 150,619
Financial Income 49,163
Financial Expenses -79,073
Income Before Income Tax and Social Contribution 120,709
Income and social contribution taxes - current -25,617
Income Tax and Social Contribution - Deferred -11,948
Effect profit from discontinued operation 0
Net Income 83,144
Recurring Net Income 52,242
Recurring EBITDA 204,872
EBITDA Margin 20.1 %

* Because of the date of the merger between Duratex and Satipel, 31.08.09, include data only from the "old" Duratex

**from 1Q 12 the data does not include discontinued operation, Deca Piazza